Beeline Medicines Corporation ("Beeline Medicines" or "the Company"), a clinical-stage biotechnology company, today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. Originally formed in July 2025, the Company's initial portfolio is comprised of five programs in-licensed from Bristol Myers Squibb (NYSE:BMY, "BMS"))), each of which is a mechanistically-guided, highly-selective therapeutic candidate with the potential to meaningfully improve the long-term health and outlook for patients living with a broad array of devastating immune-mediated conditions. With an established executive team and backed by a $300 million Series A financing led by Bain Capital, Beeline Medicines is poised to define the future of care for patients in need of life-changing treatments.

"Today marks an important milestone as Beeline Medicines debuts with a clear purpose: to deliver new, clinically significant treatment options for people living with autoimmune and inflammatory diseases," said Saqib Islam, Chief Executive Officer of Beeline Medicines. "We are building a company with the scientific and operational rigor required to urgently deliver durable, transformative innovations to address the substantial unmet needs of this patient community. Our lead program, afimetoran, is a once-daily oral investigational therapy with the potential to change the treatment paradigm for lupus patients. As our Phase 2 trial nears completion, we are preparing for pivotal development of afimetoran, and we expect several additional clinical trials to start across our pipeline over the next 12 months."

Differentiated Pipeline of Precision Therapies

Beeline Medicines is advancing a differentiated pipeline of precision therapies grounded in validated biology, powered by potential best-in-class molecular designs, and driven by an efficient clinical development strategy that prioritizes addressing high unmet patient needs. This mechanistically informed approach enables targeting of the underlying causes of immune-mediated diseases, restoration of immune balance, and the opportunity to dramatically improve outcomes for patients.

  • Afimetoran: Beeline Medicines' lead program is a selective, small molecule, once-daily, equipotent TLR7/8 inhibitor that has the potential to be a best-in-disease oral therapy for lupus. Afimetoran established early clinical proof-of-concept in a Phase 1b study in cutaneous lupus erythematosus (CLE), and in May 2025 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus (SLE). A Phase 2 study in SLE is ongoing and expected to complete in the second half of 2026, after which Beeline Medicines intends to commence its pivotal development program.
  • BMS-986326: A novel IL-2-CD25 fusion protein in Phase 1b development for atopic dermatitis and lupus (CLE and SLE); it is designed to address limitations of prior IL-2-directed therapies through improved selectivity for regulatory T cells (Treg) by slowly releasing IL-2 and providing pharmacokinetic (PK)/pharmacodynamic (PD) properties that drive potential for best-in-class Treg expansion and extended dosing intervals.
  • Lomedeucitinib (formerly BMS-986322): A potent, small molecule, once-daily, oral, allosteric TYK2 inhibitor that achieved positive proof-of-concept in a placebo-controlled Phase 2 study in plaque psoriasis, with potential for first-in-class development in rare immunological diseases.
  • Beeline Medicines' emerging pipeline includes two IND-stage next-generation biologics with novel mechanisms focused on the IL-18 and IL-10 pathways, both validated approaches for addressing inflammation across multiple indications, including in gastrointestinal inflammatory conditions.

The shared disease biology across the Company's pipeline enables long-term, sustained growth through indication expansion, combination approaches, and business development.